Halozyme Therapeutics Inc. (HALO)

16.43
NASDAQ : Health Technology
Prev Close 16.51
Day Low/High 16.18 / 16.51
52 Wk Low/High 13.24 / 19.56
Avg Volume 789.60K
Exchange NASDAQ
Shares Outstanding 145.51M
Market Cap 2.40B
EPS -0.60
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Lesotho Deputy Prime Minister, Mr. Monyane Moleleki, To Join Halo And Ms. Mojela At European Cannabis Week

Lesotho Deputy Prime Minister, Mr. Monyane Moleleki, To Join Halo And Ms. Mojela At European Cannabis Week

Halo Labs Inc. ("Halo" or the "Company") (NEO: HALO, OTCQX: AGEEF, Germany: A9KN) is pleased to announce that the Deputy Prime Minister of Lesotho, Mr.

REPEAT/Halo Labs Intends To Appoint Ms. Louisa Mojela As Chairman Of The Board Upon Closing Of Bophelo Bioscience Acquisition

REPEAT/Halo Labs Intends To Appoint Ms. Louisa Mojela As Chairman Of The Board Upon Closing Of Bophelo Bioscience Acquisition

Halo Labs Inc. ("Halo" or the "Company") (NEO: HALO, OTCQX: AGEEF, Germany: A9KN) is pleased to announce that upon closing of the previously announced acquisition of Bophelo Bioscience & Wellness (Pty) Ltd.

Halo Labs Intends To Appoint Ms. Louisa Mojela As Chairman Of The Board Upon Closing Of Bophelo Bioscience Acquisition

Halo Labs Intends To Appoint Ms. Louisa Mojela As Chairman Of The Board Upon Closing Of Bophelo Bioscience Acquisition

Halo Labs Inc. ("Halo" or the "Company") (NEO: HALO, OTCQX: AGEEF, Germany: A9KN) is pleased to announce that upon closing of the previously announced acquisition of Bophelo Bioscience & Wellness (Pty) Ltd.

REPEAT/ Halo Labs To Expand Globally And Acquire Bophelo Bioscience

REPEAT/ Halo Labs To Expand Globally And Acquire Bophelo Bioscience

Halo Labs Inc. ("Halo" or the "Company") (NEO: HALO, OTCQX: AGEEF, Germany: A9KN) is pleased to announce that it has entered into a non-binding letter of intent (LOI) for the proposed acquisition of Bophelo Bioscience & Wellness (Pty) Ltd ("Bophelo") (the...

Halo Labs To Expand Globally And Acquire Bophelo Bioscience

Halo Labs To Expand Globally And Acquire Bophelo Bioscience

Halo Labs Inc. ("Halo" or the "Company") (NEO: HALO, OTCQX: AGEEF, Germany: A9KN) is pleased to announce that it has entered into a non-binding letter of intent (LOI) for the proposed acquisition of Bophelo Bioscience & Wellness (Pty) Ltd ("Bophelo") (the...

Halozyme To Participate In Upcoming Investor Conferences

Halozyme To Participate In Upcoming Investor Conferences

SAN DIEGO, June 4, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, will participate in two upcoming investor conferences.

REPEAT/Halo Labs Products Now Available Via Online Marketplace Eaze In California And Oregon

REPEAT/Halo Labs Products Now Available Via Online Marketplace Eaze In California And Oregon

Halo Labs Inc. ("Halo" or the "Company") (NEO:HALO, OTCQX:AGEEF, Germany:A9KN) is pleased to announce their launch on the leading online cannabis marketplace Eaze to sell it products direct to consumers in California and Oregon.

Halo Labs Products Now Available Via Online Marketplace Eaze In California And Oregon

Halo Labs Products Now Available Via Online Marketplace Eaze In California And Oregon

Halo Labs Inc. ("Halo" or the "Company") (NEO:HALO, OTCQX:AGEEF, Germany:A9KN) is pleased to announce their launch on the leading online cannabis marketplace Eaze to sell it products direct to consumers in California and Oregon.

Halozyme Announces Argenx Has Selected Second Target Under ENHANZE® Technology Collaboration And License Agreement

Halozyme Announces Argenx Has Selected Second Target Under ENHANZE® Technology Collaboration And License Agreement

- Triggers $10 million milestone payment to Halozyme in the second quarter -

Halo Labs Announces Conversion Of Debentures Into Common Shares

Halo Labs Announces Conversion Of Debentures Into Common Shares

Halo Labs Inc. ("Halo" or the "Company") (NEO: HALO, OTCQX: AGEEF, Germany: A9KN) provides an update on recent conversions of the Company's 8% unsecured convertible debentures (the "Debentures").

Halozyme To Participate In Bank Of America Merrill Lynch Health Care Conference 2019

Halozyme To Participate In Bank Of America Merrill Lynch Health Care Conference 2019

SAN DIEGO, May 13, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, will participate in the Bank of America Merrill Lynch Health Care Conference 2019 in Las...

Halo To Present At The 2019 Cannabis Conference Hosted By Canaccord Genuity In NYC On May 14th

Halo To Present At The 2019 Cannabis Conference Hosted By Canaccord Genuity In NYC On May 14th

Halo Labs Inc. ("Halo" or the "Company") (NEO: HALO, OTCQX: AGEEF, Germany: A9KN) today announces that Kiran Sidhu will present at the 2019 Cannabis Conference Hosted by Canaccord Genuity at the Grand Hyatt New York in New York, NY on May 14 th, 2019 at...

Halozyme Reports First Quarter 2019 Results

Halozyme Reports First Quarter 2019 Results

- Revenue of $56.9 Million Compared to $30.9 Million in Prior-year Period -

Halo Labs Retracts Statement Regarding April Revenue; Reviewing Disclosure Approach

Halo Labs Retracts Statement Regarding April Revenue; Reviewing Disclosure Approach

Halo Labs Inc . ("Halo" or the "Company") (NEO:HALO, OTCQX:AGEEF, Germany:A9KN) retracts its press release dated May 3, 2019 wherein it disclosed estimated revenues for the month of April 2019.

Halozyme Names Dr. Alison A. Armour As Senior Vice President Of Research And Development

Halozyme Names Dr. Alison A. Armour As Senior Vice President Of Research And Development

SAN DIEGO, May 6, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced the appointment of biotechnology and pharmaceutical industry expert Alison A.

Halo Labs Reports Record Monthly Revenue In April US$3.6 Million (CDN $4.8 Million) Estimated

Halo Labs Reports Record Monthly Revenue In April US$3.6 Million (CDN $4.8 Million) Estimated

Halo Labs Inc . ("Halo" or the "Company") (NEO: HALO, OTCQX: AGEEF, Germany: A9KN) is pleased to announce that the Company achieved record revenue in April 2019 of approximately US$3.

REPEAT/Halo Labs Begins Trading On The OTCQX Market

REPEAT/Halo Labs Begins Trading On The OTCQX Market

Halo Labs Inc. ("Halo" or the "Company") (NEO: HALO, OTCQX: AGEEF, Germany: A9KN) is pleased to announce that it has qualified to trade on the OTCQX® Best Market.

Halo Labs Begins Trading On The OTCQX Market

Halo Labs Begins Trading On The OTCQX Market

Halo Labs Inc. ("Halo" or the "Company") (NEO: HALO, OTCQX: AGEEF, Germany: A9KN) is pleased to announce that it has qualified to trade on the OTCQX® Best Market.

Halozyme To Host First Quarter 2019 Financial Results Webcast And Conference Call

Halozyme To Host First Quarter 2019 Financial Results Webcast And Conference Call

SAN DIEGO, April 23, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, will webcast its Quarterly Update Conference Call for the first quarter 2019 on Tuesday,...

Halo Labs Announces Inclusion In The Horizons US Marijuana Index ETF Under The Ticker Symbols NEO: HMUS (CDN) And NEO: HMUS.U (USD)

Halo Labs Announces Inclusion In The Horizons US Marijuana Index ETF Under The Ticker Symbols NEO: HMUS (CDN) And NEO: HMUS.U (USD)

Halo Labs Inc. ("Halo" or the "Company") (NEO: HALO, OTC: AGEEF, Germany: A9KN) is pleased to announce its inclusion in the Horizons US Marijuana ETF (the "ETF") which began trading today under the NEO ticker symbols HMUS (Canadian dollar units) and HMUS.

Halo Launches Gilt™ And Hush™ Brands In Southern California For Sale To Dispensaries Through C4 Distro

Halo Launches Gilt™ And Hush™ Brands In Southern California For Sale To Dispensaries Through C4 Distro

Halo Labs Inc. ("Halo" or the "Company") (NEO: HALO, OTC: AGEEF, Germany: A9KN) is pleased to provide a progress update on its California business.

Halo Labs Reports Record Monthly Revenue In March 2019 US$2.8 Million (CDN $3.7 Million) Approximately

Halo Labs Reports Record Monthly Revenue In March 2019 US$2.8 Million (CDN $3.7 Million) Approximately

Halo Labs Inc . ("Halo" or the "Company") (NEO:HALO, OTC:AGEEF, Germany:A9KN) is pleased to announce that the Company achieved record revenue in March 2019 of approximately US$2.

Halo Labs Reports Financial Results For The Fourth Quarter And Year Ended December 31, 2018

Halo Labs Reports Financial Results For The Fourth Quarter And Year Ended December 31, 2018

Halo Labs Inc . ("Halo" or the "Company") (NEO:HALO, OTC:AGEEF, Germany:A9KN) today released its financial results for the fourth quarter and year ended December 31, 2018.

Halo Labs Granted DTC Eligibility For The U.S. OTC Market

Halo Labs Granted DTC Eligibility For The U.S. OTC Market

Halo Labs Inc. ("Halo" or the "Company") (NEO: HALO, OTC: AGEEF, Germany: A9KN) is pleased to announced it has secured eligibility by The Depository Trust Company (DTC) for its shares on the OTC.

Halo Labs Continues To Expand Nevada Business

Halo Labs Continues To Expand Nevada Business

Halo Labs Inc. ("Halo" or the "Company") (NEO: HALO, OTC: AGEEF, Germany: A9KN) is pleased to provide a progress update on its Nevada business.

Halo Labs Announces Repricing Of Convertible Debenture Units And An Increase In The Expected Size Of The Offering

Halo Labs Announces Repricing Of Convertible Debenture Units And An Increase In The Expected Size Of The Offering

Halo Labs Inc. ("Halo" or the "Company") (NEO: HALO, OTC: AGEEF, Germany: A9KN) announces that it has agreed to amend the terms of its previously announced "best efforts" offering (the "Offering") of convertible debenture units (the "Convertible Debenture...

Halo Labs Recruits Two Proven Executives To Bolster California Leadership Team

Halo Labs Recruits Two Proven Executives To Bolster California Leadership Team

Halo Labs Inc. ("Halo" or the "Company") (NEO: HALO, OTC: AGEEF, Germany: A9KN) is pleased to announce two key additions to our leadership team.

2 Stocks You Definitely Should Consider Shorting This Week

2 Stocks You Definitely Should Consider Shorting This Week

These 'Bearish Bets' are showing both technical and quantitative deterioration.

TheStreet Quant Rating: D (Sell)